| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 0.19 | 58.3% | 69.3% |
| Total Income | 0.19 | 58.3% | 69.3% |
| Expenditure | 3.03 | 23.7% | 0.0% |
| PBT | -2.62 | 28.6% | 18.6% |
| Net Profit | -2.62 | 28.6% | 18.6% |
| OPM | — | ||
| NPM | — | ||
| EPS | -0.32 | 40.7% | 21.9% |
Lipocine Inc. Announces Q2 2026 Financial Results and Corporate Update
04 Aug 2026 · 4 Aug, 3:41 pm
Summary
Lipocine Inc. announced its financial results for the second quarter ended June 30, 2026, reporting a net loss of $2.6 million, or ($0.32) per diluted share. Royalty revenue from TLANDO sales saw an increase to $190,000 for the quarter. For the six-month period, the net loss was $6.3 million, with total revenues of $309,000 primarily from TLANDO royalties. The company also provided a corporate update on its drug development pipeline, including LPCN 1154 for postpartum depression and LPCN 2201 for major depressive disorder.
Key Highlights
- 1
Lipocine Inc. reported a net loss of $2.6 million, or ($0.32) per diluted share, for the second quarter ended June 30, 2026.
- 2
Royalty revenue from TLANDO sales increased to $190,000 for the three months ended June 30, 2026, up from $123,000 in the prior year period.
- 3
For the six months ended June 30, 2026, the company reported a net loss of $6.3 million, or ($0.84) per diluted share.
- 4
Total revenues for the six months ended June 30, 2026 were $309,000, consisting entirely of royalty revenue from TLANDO sales.
- 5
Research and development expenses for the six-month period ended June 30, 2026 were $4.8 million, an increase driven by costs related to the LPCN 1154 Phase 3 study.
- 6
Unrestricted cash, cash equivalents, and marketable investment securities stood at $23.3 million as of June 30, 2026, an increase from $14.9 million at December 31, 2025.
Management Comments
Mahesh V. Patel
We believe that these results align with the established antidepressant profile of intravenous brexanolone and indicate a potential development path for LPCN 1154. We have requested a guidance meeting with the FDA and the meeting is scheduled for the third quarter of 2026. We have initiated a new placebo controlled clinical trial for PPD to complement the existing LPCN 1154 clinical database, and to further characterize the efficacy and safety of LPCN 1154. We plan to submit a protocol for a Phase 2 study to the FDA, and we may initiate a study to evaluate LPCN 2201 for MDD. We plan to submit a protocol for a Phase 2 study to the FDA and we may initiate a study to evaluate LPCN 2203 for essential tremor.
Informational and educational content only. Not investment advice.